Closing the Gap between Urban and Rural HPV Vaccination Rates

Tuesday, September 18, 2018
12:00 pm - 1:00 pm Eastern/ 9:00 am - 10:00 am Pacific

Register Here

In addition to a yearly flu vaccine, CDC recommends three vaccines for adolescents to protect against serious diseases: meningococcal conjugate vaccine, HPV vaccine, and Tdap vaccine. Nationally, HPV vaccination rates have been increasing in recent years, and rates of Tdap and meningococcal conjugate vaccine have been high for several years. However, recent data have shown that fewer adolescents in rural areas are getting the HPV and meningococcal conjugate vaccines compared to adolescents in urban areas.

This webinar will highlight the latest data on adolescent vaccination coverage nationally and among rural areas, examine various factors that may influence uptake of the HPV vaccine in rural communities, and present evidence-based strategies to help address this disparity.

Join the Rural Health Information Hub on Tuesday, September 18 at 12:00 PM ET for a webinar titled, “Closing the Gap between Urban and Rural HPV Vaccination Rates.”

Featured Speakers:

Tanja Walker, MPH, Epidemiologist, CDC’s National Center for Immunization and Respiratory Diseases will discuss the 2017 National Immunization Survey-Teen results recently published in CDC’s Morbidity and Mortality Weekly Report. This report provides the latest coverage estimates for the vaccines routinely recommended for adolescents at the national, state, and selected local levels, and some U.S. territories.
Robin C. Vanderpool, DrPH, Associate Professor, Department of Health, Behavior & Society, University of Kentucky (UK) College of Public Health will provide an overview of the burden of HPV-associated cancers in rural communities, HPV vaccine knowledge/awareness differences between rural/urban populations, and the unique challenges and opportunities associated with rural HPV vaccination.
Electra D. Paskett, PhD, Marion N. Rowley Professor of Cancer Research, The Ohio State University will highlight the development of an HPV vaccination intervention and its implementation in a full-randomized control trial then as a pilot dissemination study in Ohio Appalachia.